BrendaMarieSandmaierMDFASCT

Hematologic Oncology

Deputy Director and Professor, Translational Science and Therapeutics Professor, Division of Hematology and Oncology, University of Washington School of Medicine

Join to view full profile

Dr. Sandmaier is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sandmaier's full profile

Already have an account?

Office
Fred Hutchinson Cancer Center
1100 Fairview Ave N
Seattle, WA 98109
Phone+1 206-667-4409

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1986 - 1988
Kaiser Permanente Northern California (Santa Clara)Residency, Internal Medicine, 1983 - 1986
University of AlbertaClass of 1983, MD
University of AlbertaBSc, Genetics, Honors, 1979

Certifications & Licensure

CA State Medical License 1985 - Present
WA State Medical License 1985 - 2025
HI State Medical License 2018 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Start of enrollment: 1999 Nov 01
Completed
Not Applicable
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Start of enrollment: 2001 Nov 01
Completed
Phase 2
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant Start of enrollment: 2003 May 01
Completed
Phase 1, Phase 2
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Start of enrollment: 2003 Sep 01
Completed
Phase 1, Phase 2
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Start of enrollment: 2003 May 01
Completed
Phase 2
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia Start of enrollment: 2005 Feb 01
Completed
Phase 2
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 2
Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 2005 Apr 01
Completed
Phase 1, Phase 2
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Start of enrollment: 2006 Jan 01
Completed
Phase 2
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 1, Phase 2
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Nov 01
Completed
Phase 3
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2010 Dec 01
Completed
Phase 2
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2011 Jan 25
Completed
Phase 2
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Start of enrollment: 2017 Oct 24
Suspended
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2205 citations
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frédéric Baron, Brenda M. Sandmaier
Blood. 2005-10-15
1376 citations
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
Leo Luznik, Paul O'Donnell, Heather J. Symons, Allen R. Chen, M. Susan Leffell
Biology of Blood and Marrow Transplantation. 2008-06-01
384 citations
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgraf...
Dietger Niederwieser, Michael B. Maris, Judith A. Shizuru, Effie W. Petersdorf, Ute Hegenbart
Blood. 2003-02-15

Journal Articles

Disability Related to Chronic Graft-Versus-Host Disease After Alternative Donor Hematopoietic Cell Transplantation
Mary E Flowers, Brenda M Sandmaier, Rachel B Salit, Colleen Delaney, Filippo Milano, Stephanie J Lee, Haematologica
Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma
Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica

Abstracts/Posters

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...
Brenda M Sandmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Brenda M. Sandmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measur...
Brenda M Sandmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
Brenda M Sandmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
Brenda M Sandmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell ...
Brenda M Sandmaier, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Other

Determining eligibility for allogeneic hematopoietic cell transplantation
Sandmaier BM, Deeg HJ
http://www.uptodate.com/contents/determining-eligibility-for-allogeneic-hematopoietic-cell-transplan
UpToDate, Wolters Kluwer Health - 2013-03-29
Determining eligibility for autologous hematopoietic cell transplantation
Sandmaier BM, Deeg HJ, Holmberg LA
http://www.uptodate.com/contents/determining-eligibility-for-autologous-hematopoietic-cell-transplan
UpToDate, Wolters Kluwer Health - 2012-03-06

Press Mentions

Dr. Brenda Sandmaier Named President of American Society for Transplantation and Cellular TherapyApril 26th, 2022
Shop TalkSeptember 5th, 2020
New Leaders at ASTCT and CIBMTR Provide Guidelines and Measures for Combating COVID-19 and Protecting Transplant PatientsJune 1st, 2020
Join now to see all

Grant Support

Allogeneic HCT For Hematologic Malignancies: Immune ManipulationsNational Cancer Institute2009–2012
Nonmyeloablative Allografts In Dla-Haploidentical Dogs: Engraftment And GVHDNational Heart, Lung, And Blood Institute2007–2010
Core--Protocol Management And Coordination Of Multi-Center TrialsNational Heart, Lung, And Blood Institute2006–2010
Astatine-211 Conditioning For Nonmyeloablative Hematopoietic Stem Cell AllograftsNational Cancer Institute2006–2010
Mixed Chimerism In The Treatment Of LeukemiasNational Cancer Institute2004–2008
Nonmyeloablative Allografts In Dla-Haploidentical Dogs:National Heart, Lung, And Blood Institute2006
Nonmyeloablative Grafts In Littermate DogsNational Heart, Lung, And Blood Institute2004–2005
Nonmyeloablative Grafts In LittermatesNational Heart, Lung, And Blood Institute2001–2003
Nomyeloablative Conditioning Regimens--Mixed ChimerismNational Heart, Lung, And Blood Institute1996–2000
Role Of Adhesion Molecules In Graft ResistanceNational Cancer Institute1992–1996
Immunotherapy Following Transplant For Breast CancerNational Cancer Institute1995
Mechanism Of Antibody Facilitated Marrow EngraftmentNational Cancer Institute1990–1994

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member